Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas

Diagnostic Cytopathology

Volumn 41, Issue 4, 2013, Pages 308-315

  Monaco, Sara E ^a   Wu, Yue ^b   Teot, Lisa A ^c   Cai, Guoping ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

breast cancer; estrogen receptor; fine needle aspiration biopsy; fluorescence in situ hybridization; human epidermal growth factor receptor 2; immunohistochemistry; progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HEALTH STATUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BONE TUMOR; BREAST TUMOR; GENE EXPRESSION REGULATION; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; SOFT TISSUE TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876497547     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21841     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Cordera F, Jordan VC,. Steroid receptors and their role in the biology and control of breast cancer growth. Semin Oncol 2006; 33: 631-641.
3. Prowell TM, Armstrong DK,. Selecting endocrine therapy for breast cancer: What role does HER-2/neu status play? Semin Oncol 2006; 33: 681-687.
4. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
5. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN,. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003; 78: 105-118.
6. Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V,. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999-2004. Cancer 2008; 112: 737-747.
7. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 719-726.
8. Gown AM,. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008; 21 (Suppl 2): S8-S15.
9. Kerbel RS,. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res. 1990; 55: 87-132.
10. Nizzoli R, Bozzetti C, Naldi N, et al. Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens of primary breast carcinomas. Cancer. 2000; 90: 61-66.
11. Lofgren L, Skoog L, von Schoultz E, et al. Hormone receptor status in breast cancer-a comparison between surgical specimens and fine needle aspiration biopsies. Cytopathology 2003; 14: 136-142.
12. Moriki T, Takahashi T, Ueta S, Mitani M, Ichien M,. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: Correlation with histologic sections determinations and diagnostic pitfalls. Diagn Cytopathol 2004; 30: 251-256.
13. Sneige N,. Utility of cytologic specimens in the evaluation of prognostic and predictive factors of breast cancer: Current issues and future directions. Diagn Cytopathol 2004; 30: 158-165.
14. Sumiyoshi K, Shibayama Y, Akashi S, et al. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: Can cytology specimens take the place of tissue sections? Oncol Rep 2006; 15: 803-808.
15. Briffod M, Hacene K, Le Doussal V,. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases. Mod Pathol 2000; 13: 841-850.
16. Hanley KZ, Birdsong GG, Cohen C, Siddiqui MT,. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: Comparison on cell block, needle-core, and tissue block preparations. Cancer Cytopathol 2009; 117: 279-288.
17. Ross JS, Fletcher JA,. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16: 413-428.
18. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010; 134: 907-922.
19. Wolff AC, Hammond ME, Schwartz JN, et al.; American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43.
20. Beatty BG, Bryant R, Wang W, et al. HER-2/neu detection in fine-needle aspirates of breast cancer: Fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol 2004; 122: 246-255.
21. Bofin AM, Ytterhus B, Martin C, O'Leary JJ, Hagmar BM,. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 2004; 122: 110-119.
22. Abati A, Simsir A,. Breast fine needle aspiration biopsy: Prevailing recommendations and contemporary practices. Clin Lab Med 2005; 25: 631-654.
23. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD,. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996; 74: 1445-1451.
24. Harvey JM, Clark GM, Osborne CK, Allred DC,. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
25. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000; 89: 111-117.
26. Bedard YC, Pollett AF, Leung SW, O'Malley FP,. Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status. Acta Cytol 2003; 47: 979-984.
27. Krishnamurthy S,. Applications of molecular techniques to fine-needle aspiration biopsy. Cancer 2007; 111: 106-122.
28. Umekita Y, Sagara Y, Yoshida H,. Estrogen receptor mutations and changes in estrogen receptor and progesterone receptor protein expression in metastatic or recurrent breast cancer. Jpn J Cancer Res. 1998; 89: 27-32.
29. Santinelli A, Pisa E, Stramazzotti D, Fabris G,. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008; 122: 999-1004.
30. Lyng MB, Laenkholm AV, Pallisgaard N, Vach W, Knoop A, Bak M, Ditzel HJ,. Intratumor genetic heterogeneity of breast carcinomas as determined by fine needle aspiration and TaqMan low density array. Cell Oncol. 2007; 29: 361-372.